{"id":41545,"date":"2025-09-16T16:26:12","date_gmt":"2025-09-16T08:26:12","guid":{"rendered":"https:\/\/flcube.com\/?p=41545"},"modified":"2025-09-17T00:54:57","modified_gmt":"2025-09-16T16:54:57","slug":"fovinaciclib-cdk4-6-breaks-ground-in-breast%e2%80%91cancer-therapy","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=41545","title":{"rendered":"Fovinaciclib CDK4\/6 Breaks Ground in Breast\u2011Cancer Therapy"},"content":{"rendered":"\n

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (HKG: 2196<\/a>, SHA: 600196<\/a>)<\/strong> announced that its subsidiary Avanc Pharmaceutical Co., Ltd.<\/strong> has secured National Medical Products Administration (NMPA)<\/strong> approval for a new indication of fovinaciclib<\/strong>, a next\u2011generation CDK4\/6 inhibitor. The drug is now authorized for use in combination with an aromatase inhibitor as first\u2011line endocrine therapy in adults with hormone\u2011receptor (HR)\u2011positive, HER2\u2011negative locally advanced or metastatic breast cancer.<\/p>\n\n\n\n

Key Highlights<\/h4>\n\n\n\n
Feature<\/th>Detail<\/th><\/tr><\/thead>
Drug<\/strong><\/td>Fovinaciclib<\/strong> \u2013 oral, potent, highly selective CDK4\/6 inhibitor with a novel molecular scaffold<\/td><\/tr>
New Indication<\/strong><\/td>Combination with aromatase inhibitor for initial endocrine therapy in HR\u2011positive, HER2\u2011negative breast cancer<\/td><\/tr>
Prior Approval<\/strong><\/td>May\u202f2025 \u2013 fovinaciclib + fulvestrant for recurrent\/metastatic HR\u2011positive, HER2\u2011negative breast cancer after endocrine therapy<\/td><\/tr>
Intellectual Property<\/strong><\/td>Independent IP owned by Fosun Pharmaceutical Group<\/td><\/tr>
Regulatory Status<\/strong><\/td>Included in China\u2019s 2018 \u201cMajor New Drug Innovation\u201d science\u2011and\u2011technology project<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Clinical Significance<\/h4>\n\n\n\n